Table 3.
Clinical characteristic and outcomes of patients with NPM1 mutation or fusion genes in FLT3-ITD AML
| Characteristics |
FLT3-ITD + NPM1 + Fusion − |
FLT3-ITD + Fusion + NPM1 − |
P valuea |
|---|---|---|---|
| n | 31 | 24 | |
|
Age, years Median(range) |
52 (14–76) | 36 (12–65) | 0.007 |
|
Male n (%) |
12 (38.7) | 11 (45.8) | 0.254 |
|
WBC at diagnosis, × 109/L Median(range) |
31.4 (1.3–405.1) | 10.8 (0.7–306.9) | 0.278 |
|
Blast in BM, % Median(range) |
68.8 (21.2–96.4) | 56.4 (11.2–95.6) | 0.543 |
| FAB subtype | 0.671 | ||
| M0 | 0 (0) | 0 (0) | |
| M1 | 1 (3.3) | 1 (4.2) | |
| M2 | 8 (26.7) | 8 (33.3) | |
| M4 | 13 (43.3) | 9 (37.5) | |
| M5 | 6 (20.0) | 5 (20.8) | |
| M6 | 0 (0) | 1 (4.2) | |
| Unclassified | 0 (0) | 0 (0) | |
| Secondary-AML | 2 (6.7) | 0 (0) | |
| Karyotype | 0.015 | ||
| Favorable | 0 (0) | 7 (29.2) | |
| Intermediate | 27 (87.1) | 13 (54.2) | |
| Normal | 22 (71) | 9 (37.5) | 0.007 |
| Others | 5 (16.1) | 4 (16.7) | |
| Unfavorable | 2 (6.5) | 3 (12.5) | |
| Failed | 2 (6.5) | 1 (4.2) | |
| Immunophenotype | |||
| CD34 + | 18/25 (72.0) | 20/22 (90.9) | 0.203 |
| CD13 + | 25/26 (96.3) | 18/20 (90.0) | 0.814 |
| CD33 + | 26/26 (100) | 21/22 (95.5) | 0.458 |
| CD117 + | 23/25 (92) | 21/22 (95.5) | 1.000 |
| CD64 + | 10/24 (41.7) | 5/11 (45.5) | 1.000 |
| Mutations | |||
| Average num | 3.6 | 2.2 | 0.000 |
| DNMT3A | 13/28 (46.4) | 2/22 (9.1) | 0.004 |
| Methylation-related genesb | 16/28 (57.1) | 4/22 (18.2) | 0.005 |
| CR, n (%) | |||
| Yes | 14/25 (56) | 17/24 (70.8) | 0.282 |
| Relapse in 1 year | |||
| Yes | 16/22 (72.7) | 17/20 (85) | 0.460 |
Italic values indicate significance of P value (P < 0.05)
WBC white blood count, BM bone marrow, FAB French–America–British, CR complete remission
aP-values for categorical variables are from chi-square test, P-values for continuous variables are from the Mann–Whitney test and Fisher exact test
bMethylation-related genes included DNMT3A, IDH1/2, and TET2